ARTA
BCRX icon

A.R.T. Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

A.R.T. Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-16,130
Closed -$77K – 94
2020
Q2 		$77K Buy
16,130
+3,100
+24% +$12.4K 0.12% 208
2020
Q1 		$26K Buy
+13,030
New +$35.9K 0.46% 25
2019
Q4 		– Sell
-104,930
Closed -$301K – 1334
2019
Q3 		$301K Sell
104,930
-12,600
-11% -$39.2K 0.02% 1047
2019
Q2 		$445K Buy
117,530
+34,300
+41% +$206K 0.03% 790
2019
Q1 		$677K Buy
+83,230
New +$713K 0.04% 636
2018
Q1 		– Sell
-16,452
Closed -$80K – 1496
2017
Q4 		$80K Sell
16,452
-239,214
-94% -$1.16M ﹤0.01% 1271
2017
Q3 		$1.34M Sell
255,666
-51,950
-17% -$266K 0.07% 413
2017
Q2 		$1.71M Buy
+307,616
New +$1.87M 0.09% 314
2017
Q1 		– Sell
-14,300
Closed -$90K – 1431
2016
Q4 		$90K Buy
+14,300
New +$74.4K 0.01% 1162
2016
Q2 		– Sell
-418,308
Closed -$1.18M – 1364
2016
Q1 		$1.18M Buy
418,308
+339,688
+432% +$1.51M 0.05% 517
2015
Q4 		$811K Buy
78,620
+13,995
+22% +$139K 0.04% 660
2015
Q3 		$736K Buy
+64,625
New +$862K 0.03% 736
2015
Q2 		– Sell
-242,149
Closed -$2.19M – 1478
2015
Q1 		$2.19M Buy
+242,149
New +$2.51M 0.08% 366
2014
Q4 		– Sell
-143,281
Closed -$1.4M – 1419
2014
Q3 		$1.4M Buy
143,281
+35,417
+33% +$434K 0.06% 410
2014
Q2 		$1.38M Buy
107,864
+7,625
+8% +$74.2K 0.07% 395
2014
Q1 		$1.06M Buy
+100,239
New +$1.07M 0.06% 476

Other funds holding BCRX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

A.R.T. Advisors's BCRX Position: Q3 2020 in Review

A.R.T. Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2020, closing a stake of 16,130 shares — an estimated $77K sold.

A.R.T. Advisors first reported a position in BCRX in Q1 2014 and held it in 16 quarters. The position peaked at $2.19M in Q1 2015. 154 funds tracked by Wall St. Rank hold BCRX as of Q3 2020.

  • A.R.T. Advisors reported no remaining BioCryst Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 16,130 BioCryst Pharmaceuticals shares in Q3 2020, an estimated $77K.
  • A.R.T. Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2014 and held it in 16 quarters.
  • A.R.T. Advisors's BioCryst Pharmaceuticals position peaked at $2.19M in Q1 2015.
  • 154 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2020.

Based on A.R.T. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.